PMDA drug package insert
レナジェル錠250mg
PMDA Prescription drug · 中外製薬株式会社 · package insert Jan 24, 2020
Key facts
| Brand names | レナジェル錠250mg |
|---|---|
| Nonproprietary names | セベラマー塩酸塩 |
| Companies | 製造販売元／中外製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 高リン血症治療剤（リン結合性ポリマー） |
| Therapeutic category codes | 87219 |
| YJ codes | 2190025F1036 |
| Approval numbers | 21500AMZ00032 |
| Package insert edition | 第1版 |
| Package insert date | Jan 24, 2020 |
| PMDA document key | 450045_2190025F1036_1 |
| PMDA company code | 450045 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: